Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study.

ABSTRACT:

Background

B7 homolog 3 (B7-H3), an overexpressed antigen across multiple solid cancers, represents a promising target for CAR T cell therapy. This study investigated the expression of B7-H3 across various solid tumors and developed novel monoclonal antibodies (mAbs) targeting B7-H3 for CAR T cell therapy.

Methods

Expression of B7-H3 across various solid tumors was evaluated using RNA-seq data from TCGA, TARGET, and GTEx datasets and by flow cytometry staining. B7-H3-specific mAbs were developed by immunizing mice with human B7-H3, screening with ELISA, and analyzing kinetics with surface plasmon resonance. These mAbs were used to create second-generation CAR constructs, which were evaluated in vitro and in vivo for their antitumor function.

Results

We identified four

SUBMITTER: Inthanachai T 

PROVIDER: S-EPMC11784176 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature